Direct Answer
Immunology biotechnology companies develop drugs for autoimmune and inflammatory diseases, such as rheumatoid arthritis, psoriasis, Crohn's disease and lupus. A few large antibody franchises dominate, and new entrants target oral and more selective mechanisms.
Industry Overview
Immunology Biotechnology sits within the health care sector. The first numbers to compare across companies here are sales of key immunology drugs, pipeline stage and readouts and patents and biosimilar exposure. The outside forces that move them are listed under Primary Macro Drivers.
Key Industry Metrics
- Sales of key immunology drugs: Revenue from the few leading antibody and targeted drugs in autoimmune disease. Because a handful of products dominate, trends in these drugs largely determine company results.
- Pipeline stage and readouts: Where candidates sit from early to late trials and the results coming. Later-stage candidates are closer to revenue, so check which are tied to new mechanisms rather than copies of existing ones.
- Patents and biosimilar exposure: How soon key biologics face copies from other makers. Biosimilar entry usually pushes prices down, so exposure indicates how much current revenue is at risk.
- Cash runway for small developers: Months of spending covered by cash on hand. Smaller companies without product sales rely on financing, so a short runway can mean dilution or program cuts.
- Payer coverage and rebates: Whether insurers list a drug and the discounts paid to secure placement. High rebates can make list sales look larger than net revenue, so compare gross and net figures.
Primary Macro Drivers
- Prevalence of autoimmune disease: More people with autoimmune and inflammatory conditions expands the treated population, supporting sales of marketed drugs and trial recruitment.
- Biosimilar entry on legacy antibodies: Cheaper copies of leading antibodies pull volume and price from them, which changes the share and sales of legacy franchises and opens space for newer drugs.
- New oral and targeted therapies: Oral and more selective drugs can win patients who prefer pills or have had poor responses, shifting share among drug classes and sales of key drugs.
- Payer formulary decisions: Insurers decide which drugs they cover first and which require step therapy, which sets prescription volume and rebate levels.
Major Risks
- Trial failures and safety signals: A failed study or a safety signal can remove an expected product and cut a small developer's value quickly; watch trial readouts and safety updates.
- Biosimilar price erosion: As biosimilars arrive, net prices on leading antibodies fall and rebates rise; watch net price trends and biosimilar exposure in filings.
- Reimbursement negotiation: Large payers may demand higher rebates or restrict use in return for coverage, lowering net price per prescription; watch the gross-to-net gap.
- Crowded competition among mechanisms: Many drugs target similar pathways, so a rival with better data or a pill can take share; watch pipeline stage and competitive readouts.
Industry Characteristics
| Characteristic | Profile |
|---|---|
| Cyclicality | Defensive |
| Capital Intensity | Medium |
| Regulatory Intensity | High |
| Industry Maturity | Growth |
| Geographic Importance | U.S. / Global |
Companies Associated with Immunology Biotechnology
The SEC's Standard Industrial Classification has no code that describes immunology biotechnology as a group, so there is no complete list of its filers. The companies below come from Swoopr's SEC dataset and have operations in or next to the industry. Each is classified by the SEC under its own main business.
| Company | SEC classification | Revenue | Growth | Net margin | Year |
|---|---|---|---|---|---|
| Johnson & Johnson | Pharmaceutical Preparations | $94.2 billion | 6.0% | 28.5% | FY 2025 |
| Abbvie Inc. | Pharmaceutical Preparations | $61.2 billion | 8.6% | 6.9% | FY 2025 |
| Arcutis Biotherapeutics, Inc. | Pharmaceutical Preparations | $376 million | 91.3% | -4.3% | FY 2025 |
Source: each company's own annual report as filed with the SEC (XBRL data), figures in U.S. dollars. Listing here describes a business relationship to the industry, not a recommendation. To find more companies, use the company directory and the health care hub.
Where to Go Next
The Immunology Biotechnology guide describes how the industry earns money, what to measure and what can go wrong. To see how it compares, read the neighbouring industries in the same sector, then apply the same checks to a specific company.
More in Health Care
- Health Care sector overview
- Infection Prevention Products
- Hospitals
- Laboratory Instruments
- Hospital Consumables
- Large-Cap Biotechnology
- Hospice
- Large-Cap Pharmaceuticals
- Home Health
Put it to work
Frequently Asked Questions
What are the main KPIs for the Immunology Biotechnology industry?
Key performance indicators for the Immunology Biotechnology industry include: Sales of key immunology drugs, Pipeline stage and readouts, Patents and biosimilar exposure, Cash runway for small developers, Payer coverage and rebates. Which matter most depends on the company's model, so compare them across several companies rather than relying on one.
How cyclical is the Immunology Biotechnology industry?
The Immunology Biotechnology industry is generally defensive, meaning demand tends to remain relatively stable regardless of the economic cycle. Companies in this space can provide portfolio stability during recessions, though growth may lag in strong expansions.
What are the biggest risks in the Immunology Biotechnology industry?
The primary risks for Immunology Biotechnology companies include: Trial failures and safety signals, Biosimilar price erosion, Reimbursement negotiation, Crowded competition among mechanisms. Investors should assess each company's exposure to these factors and its track record of navigating them.